Gemzar, Cisp, Sunitinib Urothelial Ca
Completed
The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Texas Cancer Center - Abilene, Abilene, Texas +22 locations
Conditions: Urothelial Cancer